Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Oxford Biomedica PLC

Division of Oxford BioMedica PLC
www.oxfordbiomedica.co.uk

Latest From Oxford Biomedica PLC

Deal Watch: Coronavirus Collaborations Reflect Industry’s Full Press Pandemic Response

Deals involving Hoth/Voltron, Vir/Xencor, Akers/Premas, WPD/CNS address coronavirus outbreak. Separately, Roche and Forge hope to develop a novel antibiotic for Gram-negative infections using the LpxC enzyme.

Deals Coronavirus COVID-19

Oxford Biomedica Transforms With New Deals, R&D Pipeline, And Manufacturing Facilities

The lentivirus gene delivery company, Oxford Biomedica, is to collaborate with Juno Therapeutics on its CAR-T and TCR-T projects, adding to the UK biotech’s transformation into a debt-free company with a growing in-house product pipeline.

Deals Gene Therapy

Gene Therapy 'Vant' Unveiled As Dainippon, Roivant Finalize $3bn Deal

Japanese firm signs definitive agreement to acquire Roivant's interests in five 'vants' initially, including new gene therapy operation, as ex-Genentech president named head of new entity.

Business Strategies Commercial

Fresh Or Frozen? Orchard Aims For Cryopreserved Gene Therapy Approvals Using Pivotal Trials With Fresh Cell Formulations

Orchard aims to submit three ex vivo autologous gene therapies for approval by the end of 2021, helped by a new regenerative medicine advanced therapy designation (for a rare primary immunodeficiency syndrome) and a breakthrough therapy designation (for another rare primary immunodeficiency).

Drug Approval Standards Gene Therapy
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
    • Vaccines
  • Services
  • Therapeutic Areas
  • Cancer
  • Neurology, Nervous System
  • Ophthalmic
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • UK
  • Parent & Subsidiaries
  • Oxford BioMedica PLC
  • Oxford Biomedica PLC
  • Senior Management
  • John Dawson, CEO
    Stuart Paynter, CFO
    Jason Slingsby, CBO
    Kyriacos Mitrophanous, CSO
    James Miskin, CTO
    Nick Page, COO
    Lisa Giles, Chief Project & Dev Officer
  • Contact Info
  • Oxford Biomedica PLC
    Phone: (44) 1865 783 000
    Windrush Court
    Transport Way
    Oxford, OX4 6LT
    UK
UsernamePublicRestriction

Register